|
ABOUT HEMATECH
Hematech, Inc was founded in 1998, with corporate headquarters in Sioux Falls, SD. Hematech is a subsidiary of Kyowa Hakko Kirin Company, Ltd. In 2002, Hematech and Kirin consolidated their transgenic bovine research programs in facilities in Sioux Falls, SD. Currently, Hematech occupies nearly 28,000 sq. ft. of laboratory space in the Sioux Falls Technology Park.
In 2003, Hematech formed a joint venture with Trans Ova Genetics. Trans Ova is one of the world's largest bovine embryo transfer companies and has extensive experience in managing cloned and genetically modified cattle. The Hematech/Trans Ova Joint Venture was formed to manage all of Hematech's animal needs, including animal work at Hematech's Research & Development Center in Sioux Center, IA and a secondary animal facility near Hudson, SD.
Currently, Hematech has four research and development programs: Epigenetics and Embryo Development, Molecular Genetics, Embryonic Cloning, Immunology and Purification Process Development. In addition, Hematech has Analytical and Quality Systems programs. Hematech's research programs are best known for their successes in producing the first transchromosomic and gene targeted cattle. |
|
 |
> Industry Partners
> Accreditations
Our Mission
To develop human polyclonal antibody drugs for treatment of disease; sharing the hopes and passions of all people involved in the struggle against human illness.
Learn more about Hematech, Inc.
Watch Video (3:00, 9.6Mb, .flv) |
|
|
